Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$10.23 USD
-0.23 (-2.20%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $10.20 -0.03 (-0.29%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.23 USD
-0.23 (-2.20%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $10.20 -0.03 (-0.29%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth D Momentum F VGM
Zacks News
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -6.25% and -1.94%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Tilray (TLRY) to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports second-quarter 2020 results.
Should You Buy Ocular Therapeutix (OCUL) Ahead of Earnings?
by Zacks Equity Research
Ocular Therapeutix (OCUL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Ocular Therapeutix (OCUL) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Ocular Therapeutix (OCUL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Small Drug Industry Prospects Bright Amid Coronavirus Gloom
by Kinjel Shah
Small drugmakers post impressive first-quarter results. Though second-quarter results may be severely impacted by the coronavirus pandemic, an improvement is expected in the second half.
Find Stocks Under $10 to Buy Amid Coronavirus Economic Reopening
by Benjamin Rains
We screened for strong 'cheap' stocks that are trading under $10 a share that investors might want to buy as the market rally continues...
Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -2.50% and -1.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Ocular Therapeutix (OCUL) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix (OCUL) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -11.90% and -1.91%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ocular Therapeutix (OCUL) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of 2.17% and -23.59%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Moving Average Crossover Alert: Ocular Therapeutix
by Zacks Equity Research
Ocular Therapeutix, Inc. (OCUL) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
Ocular Therapeutix (OCUL) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -35.71% and -35.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
by Zacks Equity Research
The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.
Implied Volatility Surging for Ocular (OCUL) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Ocular (OCUL) stock based on the movements in the options market lately.
Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
by Zacks Equity Research
Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.
Options Traders Expect Huge Moves in Ocular (OCUL) Stock
by Zacks Equity Research
Investors need to pay close attention to Ocular (OCUL) stock based on the movements in the options market lately.
Ocular's Glaucoma Drug Study Fails to Meet Primary Endpoint
by Zacks Equity Research
Ocular's (OCUL) phase III study on OTX-TP for the reduction of intraocular pressure (IOP) in patients with primary open-angle glaucoma fails to achieve primary endpoint.
Ocular Therapeutix (OCUL) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Ocular Therapeutix (OCUL) delivered earnings and revenue surprises of -7.14% and 10.31%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Ocular Therapeutix (OCUL) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Ocular Therapeutix (OCUL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recro Pharma Falls as FDA Denies Approval to Pain Candidate
by Zacks Equity Research
FDA issues complete response letter for Recro Pharma's (REPH) marketing application for pain candidate, meloxicam, for the second time.
Ocular (OCUL) Submits an sNDA for Eye Pain Drug Dextenza
by Zacks Equity Research
Ocular (OCUL) files an sNDA to the FDA for expanding the label of its eye drug, Dextenza, to treat ocular inflammation post ophthalmic surgery.
Options Traders Expect Huge Moves in Ocular Therapeutix (OCUL) Stock
by Zacks Equity Research
Ocular Therapeutix (OCUL) needs investors to pay close attention to the stock based on moves in the options market lately.